ArticlePloS one2025
Biologically-informed regional subset analysis with CatBoost for robust tissue-of-origin prediction.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate identification of cancer tissue/cell of origin (TOO/COO) is critical for diagnosis and treatment; yet existing whole-genome approaches demand extensive computation and often struggle with sparse mutation signals. Here, we introduce an informative regional subset framework that selects a small number of biologically and statistically significant 1Mbp genomic intervals to train a CatBoost prediction model. On a benchmark of 137 whole-genome samples across six cancer types, our method achieved a 4% gain in melanoma accuracy (from 88.0% using all 2,128 regions to 92.0% with 300 regions), a 4.4% gain in multiple myeloma (87.0% with 600 regions), and perfect (100%) accuracy in high-mutation cancers such as esophageal adenocarcinoma and glioblastoma with as few as 50 informative regions. When extended to 934 PCAWG samples spanning 14 cancer lineages, the same limited regional subsets matched or improved whole-genome performance, reaching up to 100% accuracy in gastrointestinal, skin, and brain cancers, demonstrating exceptional scalability. Our approach not only reduces computational burden and enhances interpretability but also provides a robust, generalizable tool for precision oncology and the diagnosis of cancers of unknown primary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.